Literature DB >> 24899976

The Prognostic Value of the Metabolic Tumor Volume in FIGO stage IA to IIB Cervical Cancer for Tumor Recurrence: Measured by F-18 FDG PET/CT.

Bum Soo Kim1, In Joo Kim2, Seong-Jang Kim3, Hyun-Yeol Nam1, Kyoung June Pak1, Keunyoung Kim1, Man Soo Yun4.   

Abstract

PURPOSE: The purpose of this study was to evaluate the prognostic value of the metabolic tumor volume (MTV), in FIGO stage IA-IIB cervical cancer patients, measured by F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) imaging.
METHODS: Forty-five patients with invasive cervical cancer who underwent FDG-PET imaging were recruited. Metabolically active tumor regions were delineated on the pretreatment FDG-PET scans by encompassing regions equal to or greater than an standardized uptake value (SUV) of 40% of the peak tumor intensity. The relationship of the metabolic tumor volume (MTV) to the disease-free survival was analyzed. The MTV of the cervical cancer was compared with pathological and clinical prognostic factors, including lymph node metastasis, parametrial invasion, the depth of invasion, resection margins, tumor differentiation and FIGO stages.
RESULTS: Cox proportional hazard regression analysis showed that the MTV was a significant independent predictor of recurrence of cervical cancer (p = 0.027). Patients with an MTV of >20 cm(3) had a significantly reduced disease-free survival compared with patients with an MTV ≤ 20 cm(3) (p = 0.029). The correlation of the MTV with traditional prognostic factors showed significantly higher values in patients that were lymph node (LN) metastasis positive (p = 0.028) and parametrial invasion positive (p = 0.022). The MTV significantly differed among the groups according to tumor differentiation (p = 0.0319) and FIGO stage (p = 0.001).
CONCLUSION: The MTV measured by FDG-PET was an independent prognostic factor for tumor recurrence in patients with stage IA-IIB cervical cancer. These findings must be confirmed by large population based prospective studies.

Entities:  

Keywords:  Cervical cancer; FDG-PET; Metabolic tumor volume; Prognosis; Tumor recurrence

Year:  2010        PMID: 24899976      PMCID: PMC4042947          DOI: 10.1007/s13139-010-0062-8

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  22 in total

1.  Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer.

Authors:  Tom R Miller; Edward Pinkus; Farrokh Dehdashti; Perry W Grigsby
Journal:  J Nucl Med       Date:  2003-02       Impact factor: 10.057

2.  Magnetic resonance imaging in carcinoma cervix--does it have a prognostic relevance.

Authors:  Tejinder Kataria Sethi; N K Bhalla; A N Jena; S Rawat; R Oberoi
Journal:  J Cancer Res Ther       Date:  2005 Apr-Jun       Impact factor: 1.805

3.  Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma.

Authors:  Peng Xie; Jin-Bo Yue; Han-Xi Zhao; Xin-Dong Sun; Li Kong; Zheng Fu; Jin-Ming Yu
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-20       Impact factor: 4.553

4.  Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial.

Authors:  George A Plataniotis; Maria-Ekaterini Theofanopoulou; Anna Kalogera-Fountzila; Afroditi Haritanti; Elisabeta Ciuleanou; Nicolae Ghilezan; Nikolaos Zamboglou; Athanasios Dimitriadis; Ioannis Sofroniadis; George Fountzilas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

5.  Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value.

Authors:  Sheng-Chieh Chan; Joseph Tung-Chieh Chang; Hung-Ming Wang; Chien-Yu Lin; Shu-Hang Ng; Kang-Hsing Fan; Shy-Chyi Chin; Chua-Ta Liao; Tzu-Chen Yen
Journal:  Oral Oncol       Date:  2008-05-19       Impact factor: 5.337

6.  Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer.

Authors:  Terence Z Wong; Ellen L Jones; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2004 Jan-Feb       Impact factor: 3.488

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas.

Authors:  Michael Shapiro; Mijin Yun; Jacqueline M Junkins-Hopkins; Carmela C Vittorio; Norman Schulman; Bruce H Saidman; Richard G Fried; Alain H Rook; Abass Alavi
Journal:  J Am Acad Dermatol       Date:  2002-10       Impact factor: 11.527

9.  Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients.

Authors:  R D Alvarez; M E Potter; S J Soong; F L Gay; K D Hatch; E E Partridge; H M Shingleton
Journal:  Gynecol Oncol       Date:  1991-11       Impact factor: 5.482

10.  Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy.

Authors:  Young Mi Seol; Bo Ran Kwon; Moo Kon Song; Young Jin Choi; Ho Jin Shin; Joo Seop Chung; Goon Jae Cho; Jin Chun Lee; Byung Joo Lee; Soo Geun Wang; Hak Jin Kim; Won Taek Kim; Seung Jang Kim; Eun Young Yun
Journal:  Acta Oncol       Date:  2010       Impact factor: 4.089

View more
  20 in total

1.  Expression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survival.

Authors:  Weipei Zhu; Xiaohong Pan; Feng Li; Yongshen Zhang; Xueguan Lu
Journal:  Tumour Biol       Date:  2012-05-25

2.  Primary tumor SUVmax on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy.

Authors:  Shigetaka Yagi; Tamaki Yahata; Yasushi Mabuchi; Yuko Tanizaki; Aya Kobayashi; Michihisa Shiro; Nami Ota; Sawako Minami; Masaki Terada; Kazuhiko Ino
Journal:  Mol Clin Oncol       Date:  2016-07-07

3.  Pretreatment metabolic tumour volume and total lesion glycolysis are not independent prognosticators for locally advanced cervical cancer patients treated with chemoradiotherapy.

Authors:  Ozan Cem Guler; Nese Torun; Berna Akkus Yildirim; Cem Onal
Journal:  Br J Radiol       Date:  2018-01-10       Impact factor: 3.039

4.  Prognostic Value of Metabolic Activity Measured by (18)F-FDG PET/CT in Patients with Advanced Endometrial Cancer.

Authors:  Hyun Jeong Kim; Jiyoun Choi; Yong Hyu Jeong; Kwan Hyeong Jo; Jae-Hoon Lee; Arthur Cho; Mijin Yun; Jong Doo Lee; Young Tae Kim; Won Jun Kang
Journal:  Nucl Med Mol Imaging       Date:  2013-09-06

5.  Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT.

Authors:  Chulhan Kim; Hyun Hoon Chung; So Won Oh; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2013-04-04

6.  Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer.

Authors:  Su Woong Yoo; Jahae Kim; Ari Chong; Seong-Young Kwon; Jung-Joon Min; Ho-Chun Song; Hee-Seung Bom
Journal:  Nucl Med Mol Imaging       Date:  2012-09-05

7.  Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

Authors:  Laura Evangelista; Anna Rita Cervino; Cristina Ghiotto; Tania Saibene; Silvia Michieletto; Bozza Fernando; Enrico Orvieto; Valentina Guarneri; Pierfranco Conte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-31       Impact factor: 9.236

8.  A preliminary investigation into textural features of intratumoral metabolic heterogeneity in (18)F-FDG PET for overall survival prognosis in patients with bulky cervical cancer treated with definitive concurrent chemoradiotherapy.

Authors:  Kung-Chu Ho; Yu-Hua Dean Fang; Hsiao-Wen Chung; Tzu-Chen Yen; Tsung-Ying Ho; Hung-Hsueh Chou; Ji-Hong Hong; Yi-Ting Huang; Chun-Chieh Wang; Chyong-Huey Lai
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-07-06

9.  Usefulness of Combined Metabolic-Volumetric Indices of (18)F-FDG PET/CT for the Early Prediction of Neoadjuvant Chemotherapy Outcomes in Breast Cancer.

Authors:  Hyung-Jun Im; Yu Kyeong Kim; Yong-Il Kim; Jong Jin Lee; Won Woo Lee; Sang Eun Kim
Journal:  Nucl Med Mol Imaging       Date:  2012-11-17

Review 10.  Prognostic significance of volume-based PET parameters in cancer patients.

Authors:  Seung Hwan Moon; Seung Hyup Hyun; Joon Young Choi
Journal:  Korean J Radiol       Date:  2012-12-28       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.